Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
Giacomo SgallaClaudia FranciosaJacopo SimonettiLuca RicheldiPublished in: Expert opinion on investigational drugs (2020)
Pamrevlumab was effective and safe in patients in a placebo-controlled phase 2 trial, demonstrating its potential to become an alternative therapeutic option for IPF; however, the feasibility of intravenous administration in clinical practice may be a hurdle to its use as a first-line treatment. Further studies are necessary to assess its effects when administered with pirfenidone or nintedanib and this could open up a new era of combined therapeutic approaches for IPF.
Keyphrases
- idiopathic pulmonary fibrosis
- interstitial lung disease
- end stage renal disease
- clinical practice
- ejection fraction
- newly diagnosed
- chronic kidney disease
- placebo controlled
- minimally invasive
- prognostic factors
- high dose
- randomized controlled trial
- double blind
- study protocol
- radiation therapy
- low dose
- phase ii
- phase iii